In early February, the U.S. Federal Trade Commission published a proposed order that fines telehealth and discount prescription provider GoodRX $1.5 milllion. Though part of the case involves deception — one of two prongs under the FTC Act — the case also raises the first-of-its-kind use of the Health Breach Notification Rule. To help better understand the novel and complex issues embedded in the case, IAPP Editorial Director Jedidiah Bracy, CIPP, caught up with WilmerHale Partner Kirk Nahra, CIPP/US, to discuss some of the takeaways privacy pros in any industry vertical should consider.
Listen Here
10 Feb. 2023
Top takeaways from the FTC-GoodRx case: A chat with Kirk Nahra
Related stories
Notes from the IAPP Canada: CPS25 zeroes in on the issues that matter most
A view from DC: An updated NIST Privacy Framework
Handsets, headsets and hyperscreens: Emerging ideas for immersive experiences and the importance of governance by design
Notes from the Asia-Pacific region: India strides ahead on the digital front
New developments in global adequacy capabilities
This article is eligible for Continuing Professional Education credits. Please self-submit according to CPE policy guidelines.